The goals of our Phase 1 research program at MSKCC are to: 1) identify promising new therapeutic agents;2) preclinical study of these agents to better understand the mechanism of action of these agents;3) extension of preclinical data into rational patient-oriented clinical trials through dose-finding (Phase I) single agent or combination trials;and 4) identification of innovative approaches to Phase 1 study conduct using novel biostatistical, pharmacokinetic, and pharmacodynamic approaches. A close collaboration between laboratory and clinical scientists are required to accomplish these goals. We will focus on projects as illustrative of the lab-to-clinic translational research at MSKCC: (1) Hsp90 is an abundant cellular chaperone that is required for refolding of unfolded proteins and we have demonstrated that inhibition of Hsp90 induces the rapid degradation of HER2 and loss of its expression on the membrane. We took advantage of this unique property of Hsp90 inhibitors and developed a novel non-invasive method for imaging loss of HER2 expression in the tumors. This molecular imaging approach will provide a platform for in vivo testing of HspQO inhibitors in patients;(2) Cytotoxic chemotherapy continues to be the mainstay of treatment for many cancers. Since most conventional anti-cancer agents impart damage to the genome and therefore also activate cell cycle checkpoints, pharmacological disruption of collateral checkpoint pathways might create 'synthetic lethality'selectively in tumors and represent a significant therapeutic opportunity;the basic understanding of the targets and sequence of treatment is necessary for our clinical study design;(3) Epidermal growth factor tyrosine kinase inhibitors (EGFR TKIS) such as gefitinib and erlotinib have changed how we treat non-small lung cancers. Certain EGFR kinase domain mutations underlie dramatic sensitivity to EGFR TKIS but we have shown that acquired resistance to EGFR TKIS invariably occurs and is often associated with the T790M resistance mutation of EGFR and represents a significant problem for patients with lung cancer. Further understanding of the mechanisms underlying this process will facilitate ways to both to both overcome and suppress the development of acquired resistance. These projects focus our effort on building strong bench-to-bedside and back-to-bench research. This iterative research approach to develop novel targeted therapy is critical to our success in the fight against cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01CA069856-18S1
Application #
8628943
Study Section
Special Emphasis Panel (ZCA1-SRRB-K (O1))
Program Officer
Ivy, S Percy
Project Start
1995-05-16
Project End
2014-02-28
Budget Start
2013-03-01
Budget End
2014-02-28
Support Year
18
Fiscal Year
2013
Total Cost
$228,694
Indirect Cost
$99,342
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Iasonos, Alexia; O'Quigley, John (2014) Adaptive dose-finding studies: a review of model-guided phase I clinical trials. J Clin Oncol 32:2505-11
Abrams, Jeffrey S; Mooney, Margaret M; Zwiebel, James A et al. (2013) Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials. J Natl Cancer Inst 105:954-9
Iyer, Gopa; Morris, Michael J; Rathkopf, Dana et al. (2012) A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors. Cancer Chemother Pharmacol 69:1089-97
Goldlust, S A; Hsu, M; Lassman, A B et al. (2012) Seizure prophylaxis and melanoma brain metastases. J Neurooncol 108:109-14
Daher, May; Lacouture, Mario E; Rathkopf, Dana et al. (2011) Case series of dermatologic events associated with the insulin-like growth factor receptor 1 inhibitor cixutumumab. J Clin Oncol 29:e638-40
Paik, Paul K; Rudin, Charles M; Pietanza, Maria C et al. (2011) A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer 74:481-5
Paik, Paul K; Rudin, Charles M; Brown, Andrew et al. (2010) A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemother Pharmacol 66:1079-85
Janjigian, Yelena Y; Lee, Wooin; Kris, Mark G et al. (2010) A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors. Cancer Chemother Pharmacol 65:833-8
Tse, Archie N; Klimstra, David S; Gonen, Mithat et al. (2008) A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors. Clin Cancer Res 14:6704-11
Iasonos, Alexia; Wilton, Andrew S; Riedel, Elyn R et al. (2008) A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies. Clin Trials 5:465-77

Showing the most recent 10 out of 20 publications